Target intelligence / Profile preview

Sorting nexin-27 (SNX27)

Target
SNX27
Molecular classification
Sorting nexin family protein, Endosomal trafficking adaptor, PDZ domain-containing protein, Retromer complex-associated protein, Other
01

Overview

Sorting nexin-27 (SNX27) is a unique member of the sorting nexin protein family, characterized by the presence of a phox-homology (PX) domain, a FERM domain, and an N-terminal PDZ domain (unique among sorting nexins). SNX27 functions as a key adaptor in the endosomal protein sorting system: by binding to PDZ-binding motifs in the cytosolic tails of transmembrane cargo proteins, it mediates their interaction with the retromer complex, thereby promoting recycling from endosomes to the plasma membrane and preventing lysosomal degradation. SNX27 is highly expressed in neuronal tissue, regulates critical processes such as synaptic plasticity by controlling AMPA receptor localization, and has been implicated in several neurodevelopmental, neurodegenerative, and oncogenic processes. Its dysfunction is associated with intellectual disability, epilepsy, memory deficits, metabolic regulation disturbances, and may contribute to tumorigenesis by modulating cell surface receptor availability and intracellular signaling pathways.

Other names
SNX27KIAA0488methamphetamine-responsive transcript 1MRT1MY014MGC20471sorting nexin family member 27
02

Mechanism of action

No small-molecule drugs with defined mechanisms of action specifically target SNX27; mechanisms described are via modulation of SNX27-mediated recycling of PDZ motif-containing cargoes, affecting surface expression of receptors such as AMPA-type glutamate receptors or β2-adrenergic receptors.

03

Biological functions

Endosomal protein sorting and traffickingEndocytic recyclingRegulation of synaptic plasticityModulation of neurotransmitter receptor trafficking (notably AMPA and NMDA receptors)Regulation of membrane protein compositionWnt signaling regulationGlucose transporter recyclingT-cell activationMaintenance of neuronal excitability
04

Disease associations

Neurodegenerative disease (e.g., Alzheimer’s disease, via amyloid precursor protein trafficking)Intellectual disabilityEpilepsyAutism spectrum disordersWorking memory deficitsCancer (oncogenic signaling, tumorigenesis)Drug addiction/psychostimulant response
05

Safety considerations

Potential safety concerns could arise from broad effects on endosomal recycling, impacting multiple cell-surface proteins essential for neuronal function, metabolism, and cell signaling.Disruption of SNX27 has been linked to intellectual disability and memory impairment in preclinical studies.Direct targeting is largely unexplored; on-target side effects are unknown but may include neuronal or immunological dysfunction due to dysregulated receptor recycling.
06

Interacting drugs

No approved drugs are known to specifically target SNX27 directly as a primary therapeutic target. However, indirect interactions via regulation of SNX27-dependent cargoes are described; some psychostimulants (such as methamphetamine) may modulate SNX27 expression.
07

Biomarkers

At present, SNX27 itself is not established as a clinical biomarker for patient selection or efficacy monitoring. However, altered SNX27 levels may have biomarker potential in neurodevelopmental or neurodegenerative diseases, and cancer is postulated but not clinically validated.

Beyond the preview

Go deeper on Sorting nexin-27 (SNX27).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sorting nexin-27 (SNX27).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call